Print Page | Close Window

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$29.32 + 0.311.07%122,093
Previous CloseToday's OpenIntraday HighIntraday Low
$29.01$29.01$29.56$28.97
Exchange: NASDAQ (US Dollar)
07/19/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
06/26/18
Download Documentation Analyst Meeting Transcript
05/01/18
Download Documentation Investor Presentation
04/26/18
Download Documentation Q1 2018 Earnings Call Transcript

All Recent News

DateTitle 
07/16/18AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
07/11/18AtriCure to Announce Second Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2018 financial results on Wednesday, August 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 1, 2018 to discuss its second quarter 2018 financial ... 
Printer Friendly Version
06/12/18AtriCure Announces 2018 Analyst and Investor Meeting
MASON, Ohio--(BUSINESS WIRE)--Jun. 12, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018, in New York City from 8:30 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will focus on clinician guest speakers to provide expert perspectives on broad trends in ... 
Printer Friendly Version
06/05/18AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
07/16/18AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
07/11/18AtriCure to Announce Second Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2018 financial results on Wednesday, August 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 1, 2018 to discuss its second quarter 2018 financial ... 
Printer Friendly Version
06/12/18AtriCure Announces 2018 Analyst and Investor Meeting
MASON, Ohio--(BUSINESS WIRE)--Jun. 12, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018, in New York City from 8:30 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will focus on clinician guest speakers to provide expert perspectives on broad trends in ... 
Printer Friendly Version
04/26/18AtriCure Reports First Quarter 2018 Financial Results
Worldwide revenue of $47.0 million – an increase of 13.9% year over year U.S. revenue of $38.4 million – an increase of 15.5% year over year International revenue of $8.6 million – an increase of 6.9% year over year MASON, Ohio--(BUSINESS WIRE)--Apr. 26, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
06/05/18AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes... 
Printer Friendly Version
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
11/01/16AtriCure Announces Approval for the cryoICE™ Platform in Japan
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation ... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
08/01/18 
4:30 p.m. ET
Q2 2018 AtriCure, Inc. Earnings Conference Call
08/09/18 
12:00 p.m. ET
AtriCure, Inc. at Canaccord Genuity 38th Annual Growth Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.